Literature DB >> 22460692

Prion infection promotes extensive accumulation of α-synuclein in aged human α-synuclein transgenic mice.

Eliezer Masliah1, Edward Rockenstein, Chandra Inglis, Anthony Adame, Cyrus Bett, Melanie Lucero, Christina J Sigurdson.   

Abstract

In neurodegenerative disorders of the aging population, misfolded proteins, such as PrP(Sc), α-synuclein, amyloid β protein and tau, can interact resulting in enhanced aggregation, cross seeding and accelerated disease progression. Previous reports have shown that in Creutzfeldt-Jakob disease and scrapie, α-synuclein accumulates near PrP(Sc) deposits. However, it is unclear if pre-existing human α-synuclein aggregates modified prion disease pathogenesis, or if PrP(Sc) exacerbates the α-synuclein pathology. Here, we inoculated infectious prions into aged α-synuclein transgenic (tg) and non-transgenic littermate control mice by the intracerebral route. Remarkably, inoculation of RML and mNS prions into α-synuclein tg mice resulted in more extensive and abundant intraneuronal and synaptic α-synuclein accumulation. In addition, infectious prions led to the formation of perineuronal α-synuclein deposits with a neuritic plaque-like appearance. Prion pathology was unmodified by the presence of α-synuclein. However, with the mNS prion strain there was a modest but significant acceleration in the time to terminal prion disease in mice having α-synuclein aggregates as compared with non-tg mice. Taken together, these studies support the notion that PrP(Sc) directly or indirectly promotes α-synuclein pathology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22460692      PMCID: PMC3366356          DOI: 10.4161/pri.19806

Source DB:  PubMed          Journal:  Prion        ISSN: 1933-6896            Impact factor:   3.931


  39 in total

1.  Molecular cross talk between misfolded proteins in animal models of Alzheimer's and prion diseases.

Authors:  Rodrigo Morales; Lisbell D Estrada; Rodrigo Diaz-Espinoza; Diego Morales-Scheihing; Maria C Jara; Joaquin Castilla; Claudio Soto
Journal:  J Neurosci       Date:  2010-03-31       Impact factor: 6.167

2.  Unusual topogenic sequence directs prion protein biogenesis.

Authors:  C D Lopez; C S Yost; S B Prusiner; R M Myers; V R Lingappa
Journal:  Science       Date:  1990-04-13       Impact factor: 47.728

Review 3.  A century-old debate on protein aggregation and neurodegeneration enters the clinic.

Authors:  Peter T Lansbury; Hilal A Lashuel
Journal:  Nature       Date:  2006-10-19       Impact factor: 49.962

Review 4.  Genetic mouse models of Parkinson's disease The state of the art.

Authors:  Iddo Magen; Marie-Françoise Chesselet
Journal:  Prog Brain Res       Date:  2010       Impact factor: 2.453

Review 5.  Genetically altered transgenic models of Alzheimer's disease.

Authors:  E Masliah; E Rockenstein
Journal:  J Neural Transm Suppl       Date:  2000

6.  In vivo demonstration that alpha-synuclein oligomers are toxic.

Authors:  Beate Winner; Roberto Jappelli; Samir K Maji; Paula A Desplats; Leah Boyer; Stefan Aigner; Claudia Hetzer; Thomas Loher; Marçal Vilar; Silvia Campioni; Christos Tzitzilonis; Alice Soragni; Sebastian Jessberger; Helena Mira; Antonella Consiglio; Emiley Pham; Eliezer Masliah; Fred H Gage; Roland Riek
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-15       Impact factor: 11.205

7.  Initiation and synergistic fibrillization of tau and alpha-synuclein.

Authors:  Benoit I Giasson; Mark S Forman; Makoto Higuchi; Lawrence I Golbe; Charles L Graves; Paul T Kotzbauer; John Q Trojanowski; Virginia M-Y Lee
Journal:  Science       Date:  2003-04-25       Impact factor: 47.728

Review 8.  Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs.

Authors:  Mark S Forman; John Q Trojanowski; Virginia M-Y Lee
Journal:  Nat Med       Date:  2004-10       Impact factor: 53.440

9.  Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters.

Authors:  Edward Rockenstein; Margaret Mallory; Makoto Hashimoto; David Song; Clifford W Shults; Ingrid Lang; Eliezer Masliah
Journal:  J Neurosci Res       Date:  2002-06-01       Impact factor: 4.164

10.  Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils.

Authors:  Hilal A Lashuel; Benjamin M Petre; Joseph Wall; Martha Simon; Richard J Nowak; Thomas Walz; Peter T Lansbury
Journal:  J Mol Biol       Date:  2002-10-04       Impact factor: 5.469

View more
  9 in total

Review 1.  Review: Novel treatment strategies targeting alpha-synuclein in multiple system atrophy as a model of synucleinopathy.

Authors:  E Valera; G Monzio Compagnoni; E Masliah
Journal:  Neuropathol Appl Neurobiol       Date:  2016-02       Impact factor: 8.090

2.  Interactions between S100A9 and Alpha-Synuclein: Insight from NMR Spectroscopy.

Authors:  Zigmantas Toleikis; Raitis Bobrovs; Agne Janoniene; Alons Lends; Mantas Ziaunys; Ieva Baronaite; Vytautas Petrauskas; Kristine Kitoka; Vytautas Smirnovas; Kristaps Jaudzems
Journal:  Int J Mol Sci       Date:  2022-06-17       Impact factor: 6.208

3.  What we can learn from animal models about cerebral multi-morbidity.

Authors:  Siân Baker; Jürgen Götz
Journal:  Alzheimers Res Ther       Date:  2015-01-29       Impact factor: 6.982

4.  Cross-seeding of prions by aggregated α-synuclein leads to transmissible spongiform encephalopathy.

Authors:  Elizaveta Katorcha; Natallia Makarava; Young Jin Lee; Iris Lindberg; Mervyn J Monteiro; Gabor G Kovacs; Ilia V Baskakov
Journal:  PLoS Pathog       Date:  2017-08-10       Impact factor: 6.823

5.  Combined immunotherapy with "anti-insulin resistance" therapy as a novel therapeutic strategy against neurodegenerative diseases.

Authors:  Yoshiki Takamatsu; Gilbert Ho; Wakako Koike; Shuei Sugama; Takato Takenouchi; Masaaki Waragai; Jianshe Wei; Kazunari Sekiyama; Makoto Hashimoto
Journal:  NPJ Parkinsons Dis       Date:  2017-01-23

Review 6.  Microbiome, Parkinson's Disease and Molecular Mimicry.

Authors:  Fabiana Miraglia; Emanuela Colla
Journal:  Cells       Date:  2019-03-07       Impact factor: 6.600

7.  Spatiotemporal modulations in heterotypic condensates of prion and α-synuclein control phase transitions and amyloid conversion.

Authors:  Aishwarya Agarwal; Lisha Arora; Sandeep K Rai; Anamika Avni; Samrat Mukhopadhyay
Journal:  Nat Commun       Date:  2022-03-03       Impact factor: 14.919

Review 8.  Crosstalk Between Alpha-Synuclein and Other Human and Non-Human Amyloidogenic Proteins: Consequences for Amyloid Formation in Parkinson's Disease.

Authors:  Tony Werner; Istvan Horvath; Pernilla Wittung-Stafshede
Journal:  J Parkinsons Dis       Date:  2020       Impact factor: 5.568

Review 9.  Protein Co-Aggregation Related to Amyloids: Methods of Investigation, Diversity, and Classification.

Authors:  Stanislav A Bondarev; Kirill S Antonets; Andrey V Kajava; Anton A Nizhnikov; Galina A Zhouravleva
Journal:  Int J Mol Sci       Date:  2018-08-04       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.